use in HIV acquisition has been shown. His research group conducted a prospective study of hormonal contraception in relation to HIV seroconversion and elucidated the epidemiology of human papillomavirus prevalence, incidence, and clearance—a study with significant family planning policy and health implications. Today, he is the principal investigator of four studies in Thailand supported by the National Institutes of Health, focusing on interventions to influence the association between drug use, sexual risk, and HIV treatment in HIV transmission. Additional research is being conducted in Vietnam, India, South Africa, and Tanzania.
Moupali Das, M.D., M.P.H., is director of research in the HIV Prevention Section at the San Francisco Department of Public Health and assistant clinical professor in the Divisions of Infectious Diseases and HIV/AIDS at San Francisco General Hospital, at the University of California, San Francisco. She is a board-certified infectious disease clinician–HIV specialist with research expertise in implementation science and evaluation research, in particular, using routinely collected HIV surveillance data to evaluate the impact of a comprehensive public health approach to HIV, including multilevel HIV prevention interventions. Dr. Das coauthored a key modeling study using San Francisco’s surveillance data to evaluate the effect of expanding access to antiretroviral therapy on the HIV epidemic among men who have sex with men. She has developed a novel population-based biologic indicator, community viral load, for monitoring the HIV epidemic prevention and control. Her manuscript on community viral load (Das, PLOS One 2010) has been cited as the basis for measuring community viral load in President Barack Obama’s National HIV/AIDS Strategy (NHAS) and provides the framework for the NHAS recommendation that community viral load be used as an outcome measure to evaluate the effectiveness of the strategy. Dr. Das has examined geographic and socio-demographic disparities in community viral load as well as the relationship between community viral load and new HIV infections. She is evaluating the relationship between differences in community viral load among different subpopulations in San Francisco and corresponding disparities in HIV incidence. Dr. Das is currently refining the community viral load methodology and exploring using community viral load as a marker for multiple planned multilevel HIV-prevention trials. Dr. Das has been honored by invitations to participate in the Department of Health and Human Services and Office of Management and Budget consultations on developing a parsimonious set of harmonized indicators to evaluate the impact of the NHAS and health care reform. Dr. Das has been privileged to mentor junior investigators to support publication of their manuscripts on community viral load (Castel, AIDS 2011).